CollPlant Biotechnologies Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by CollPlant Biotechnologies Ltd. on November 15, 2022, covering the month of November 2022. The registrant is a foreign private issuer based in Rehovot, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose a material corporate event and does not contain financial statements or performance data.
Material Changes and Corporate Developments
On November 15, 2022, the company announced a strategic collaboration with Tel Aviv University and Sheba Medical Center. The partnership aims to co-develop a recombinant human collagen (rhCollagen)-based 3D bioprinted human intestine model. This model is intended for drug discovery and personalized treatment of Ulcerative Colitis.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the context of the new research partnership. No unusual items were reported in this document.
Key Facts for Investor Verification
- CollPlant has entered a new R&D partnership with Tel Aviv University and Sheba Medical Center.
- The collaboration focuses on 3D bioprinted intestine models for Ulcerative Colitis treatment.
- This filing contains no financial results; investors should refer to the most recent Form 20-F for financial data.
- The press release detailing the partnership is attached as Exhibit 99.1.